CA
NZ
UK
AU
IND
US
…
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
TriSalus Life Sciences appears to focus on developing medical technologies for locoregional cancer treatment based on public disclosures. Its long-term growth drivers include regulatory approvals, positive clinical outcomes, successful commercialization and reimbursement adoption in oncology care, and broader acceptance of minimally invasive therapies. Investors may find the company attractive because it targets a large cancer-treatment market and could benefit if its clinical and regulatory programs achieve validation.
Key risks include clinical and regulatory failure, limited operating history and revenues, ongoing capital needs and dilution, and strong competition from established oncology and medical-device companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Income before tax | -47.18M | -28.84M |
| Net income | -47.19M | -28.84M |
| Selling general administrative | 12.48M | 8.75M |
| Selling and marketing expenses | 12.74M | 8.26M |
| Gross profit | 10.14M | 7.21M |
| Reconciled depreciation | 0.40M | 0.46M |
| Ebit | -44.99M | -23.29M |
| Ebitda | -44.59M | -22.82M |
| Depreciation and amortization | 0.40M | 0.46M |
| Operating income | -36.44M | -24.03M |
| Other operating expenses | 48.84M | 32.43M |
| Interest expense | 0.00M | 1.76M |
| Tax provision | 0.01M | 0.00M |
| Interest income | 0.18M | 0.00M |
| Net interest income | 0.18M | -1.76M |
| Income tax expense | 0.01M | 0.00M |
| Total revenue | 12.40M | 8.40M |
| Total operating expenses | 46.58M | 31.24M |
| Cost of revenue | 2.26M | 1.19M |
| Total other income expense net | -10.92M | -3.05M |
| Net income from continuing ops | -47.19M | -28.84M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 25.73M | 22.00M | 252.01M |
| Intangible assets | 1.13M | - | - |
| Other current assets | 2.99M | 0.21M | 0.67M |
| Total liab | 51.66M | 198.32M | 8.85M |
| Total stockholder equity | -25.94M | -176.33M | 243.16M |
| Other current liab | 0.39M | 27.04M | 0.10M |
| Common stock | 0.00M | 0.01M | 238.16M |
| Capital stock | 0.00M | 0.01M | 0.01M |
| Retained earnings | -248.38M | -186.36M | -0.11M |
| Cash | 11.78M | 9.41M | 1.33M |
| Total current liabilities | 14.69M | 32.36M | 0.10M |
| Current deferred revenue | 10.56M | 6.38M | - |
| Net debt | -10.18M | -7.45M | -1.33M |
| Short term debt | 0.35M | 0.37M | - |
| Short long term debt total | 1.59M | 1.96M | 0.54M |
| Other stockholder equity | 222.44M | 10.02M | 5.10M |
| Total current assets | 20.86M | 17.21M | 2.01M |
| Net receivables | 3.55M | 1.56M | 1.36M |
| Inventory | 2.54M | 1.47M | 1.29M |
| Accounts payable | 3.39M | 4.95M | 1.30M |
| Non currrent assets other | 0.47M | -19.46M | 250.00M |
| Non current assets total | 4.86M | 4.78M | 250.00M |
| Capital lease obligations | 1.59M | 1.96M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Investments | -1.79M | -2.26M |
| Total cash from financing activities | 13.46M | 50.77M |
| Net income | -47.19M | -28.84M |
| Change in cash | -20.64M | 25.81M |
| Begin period cash flow | 30.30M | 4.49M |
| End period cash flow | 9.66M | 30.30M |
| Total cash from operating activities | -32.31M | -22.70M |
| Issuance of capital stock | 13.50M | 52.02M |
| Depreciation | 0.40M | 0.46M |
| Change to inventory | -0.18M | -0.72M |
| Change to account receivables | -0.20M | -0.74M |
| Other cashflows from financing activities | 13.59M | 52.12M |
| Capital expenditures | 0.79M | 1.26M |
| Change in working capital | 2.30M | -0.13M |
| Stock based compensation | 0.37M | 0.11M |
| Other non cash items | 11.81M | 5.71M |
| Free cash flow | -33.10M | -23.95M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLSI TriSalus Life Sciences Inc. |
-0.15 4.13% |
3.48 | - | - | 15.33 | 30.29 | 16.95 | -5.96 |
| ABT Abbott Laboratories |
- -% |
109.40 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.41 0.41% |
98.88 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
3.74 1.22% |
310.55 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.66 1.38% |
48.35 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
6272 West 91st Avenue, Westminster, CO, United States, 80031
303 442 1222
112
| Name | Title | Year Born |
|---|---|---|
| Ms. Mary T. Szela B.S.N., M.B.A. | CEO, President & Director | 1964 |
| Mr. Sean Edward Murphy | CFO & Director | 1953 |
| Dr. Steven C. Katz F.A.C.S., M.D. | Chief Medical Officer & Chairman of Scientific Advisory Board | 1975 |
| Ms. Jennifer L. Stevens J.D. | Chief Regulatory Officer | 1961 |
| Ms. Lori Ann Santamaria | Vice President of Operations | NA |
| Dr. Bryan F. Cox Ph.D. | Chief Scientific & Manufacturing Officer | 1962 |
| Mr. James E. Young | Senior VP of Investor Relations & Treasurer | NA |
| Ms. Rachel Garcia | Marketing Manager | NA |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Senior Vice President of Corporate Development & Strategy | 1959 |
| Ms. Jodi Devlin | President of Commercial Operations | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...